Cubist Systematic Strategies LLC Invests $2.81 Million in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Cubist Systematic Strategies LLC acquired a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 119,065 shares of the company’s stock, valued at approximately $2,805,000.

A number of other large investors have also bought and sold shares of the company. Braidwell LP bought a new position in shares of Dyne Therapeutics during the 4th quarter worth $16,049,000. Brevan Howard Capital Management LP bought a new position in Dyne Therapeutics during the fourth quarter worth about $678,000. BNP Paribas Financial Markets purchased a new position in shares of Dyne Therapeutics in the fourth quarter worth about $1,578,000. Ameriprise Financial Inc. raised its position in shares of Dyne Therapeutics by 3.2% in the fourth quarter. Ameriprise Financial Inc. now owns 219,635 shares of the company’s stock valued at $5,175,000 after purchasing an additional 6,735 shares during the period. Finally, ArrowMark Colorado Holdings LLC lifted its stake in shares of Dyne Therapeutics by 3.6% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 932,231 shares of the company’s stock valued at $21,963,000 after buying an additional 32,041 shares in the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Stock Up 1.2 %

Shares of DYN stock opened at $11.44 on Friday. The business has a 50-day moving average price of $10.37 and a two-hundred day moving average price of $18.07. Dyne Therapeutics, Inc. has a 12-month low of $6.36 and a 12-month high of $47.45. The firm has a market cap of $1.30 billion, a P/E ratio of -3.21 and a beta of 1.19.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.17). As a group, research analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on DYN shares. HC Wainwright reduced their price objective on shares of Dyne Therapeutics from $46.00 to $38.00 and set a “buy” rating for the company in a research note on Friday. Piper Sandler decreased their price objective on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Scotiabank began coverage on Dyne Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 target price for the company. BMO Capital Markets started coverage on shares of Dyne Therapeutics in a report on Wednesday, March 12th. They issued an “outperform” rating and a $50.00 price target on the stock. Finally, Chardan Capital reaffirmed a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research note on Friday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $46.85.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the sale, the insider now owns 199,087 shares of the company’s stock, valued at $2,777,263.65. This trade represents a 1.29 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have sold 6,237 shares of company stock valued at $77,760. Insiders own 14.14% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.